Anticoagulation for Atrial Fibrillation
Risk Stratification Algorithm
- The American College of Cardiology recommends using the CHA₂DS₂-VASc score to determine anticoagulation need for patients with atrial fibrillation, with a score of ≥2 in men or ≥3 in women indicating a high risk of stroke 1, 3
- For patients with a CHA₂DS₂-VASc score of 0 in men or 1 in women, no anticoagulation is recommended, while a score of 1 in men or 2 in women suggests oral anticoagulation is preferred over no therapy 1, 3
- The CHA₂DS₂-VASc scoring system includes points for congestive heart failure, hypertension, age, diabetes, prior stroke or transient ischemic attack, vascular disease, and female sex 1, 4
First-Line Anticoagulant Selection
- The American College of Cardiology recommends direct oral anticoagulants (DOACs) over warfarin for patients with non-valvular atrial fibrillation, with apixaban 5 mg twice daily being the preferred agent due to its superior efficacy and safety profile 1, 2
- Apixaban is preferred for patients with prior gastrointestinal bleeding, while dabigatran 150 mg twice daily may be considered for patients with high embolic risk and low bleeding risk 1, 2
Special Clinical Scenarios
- For patients with high bleeding risk, apixaban 5 mg twice daily, edoxaban 60 mg once daily, or dabigatran 110 mg twice daily are recommended to reduce major bleeding risk 2, 4
- The American College of Cardiology recommends therapeutic anticoagulation for at least 4 weeks after cardioversion, with the decision to continue anticoagulation based on the CHA₂DS₂-VASc score rather than the success of cardioversion 2, 4
Critical Pitfalls to Avoid
- Aspirin alone or aspirin plus clopidogrel should not be used for stroke prevention in atrial fibrillation, as they are inferior to oral anticoagulation 2, 4
- Anticoagulation should not be withheld based on bleeding risk scores, but rather modifiable bleeding risk factors should be addressed 2, 3